Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antibiotic Selection00:57

Antibiotic Selection

59.3K
Overview
59.3K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

1.3K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.3K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.7K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

928
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
928
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

897
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
897
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

177
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
177

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

An evaluation of the US public-private Combating Antibiotic-Resistant Bacteria Accelerator (CARB-X) initiative.

Health affairs scholar·2026
Same author

Diffusion of HIV Prevention Advocacy in Social Networks of Persons Living with HIV in Uganda.

International journal of behavioral medicine·2026
Same author

Longitudinal Correlates of Internalized HIV Stigma Among Ugandan PLWH.

AIDS and behavior·2026
Same author

Correlates of PrEP Cascade Outcomes Among Immigrant Latino Men Who Have Sex with Men.

AIDS and behavior·2026
Same author

Bridging the Diagnostic Gap in Peripheral Arterial Disease (PAD): Leveraging Fatty Acid Binding Protein 3 (FABP3) for Biomarker-Guided Detection.

Diagnostics (Basel, Switzerland)·2026
Same author

HIV Disclosure and Prevention Advocacy Partially Mediate Advocacy Training Intervention Effect on Reduced Internalized HIV Stigma.

AIDS and behavior·2026

相关实验视频

Updated: Jan 13, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
10:49

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

11.5K

重新思考对新型抗生素的未满足需求.

Eric J Evans1,2, P Douglas Witt3, George G Zhanel4

  • 1Mossavar-Rahmani Center for Business and Government, Harvard Kennedy School, Cambridge, MA, USA. eevans@massmedangels.com.

The Journal of antibiotics
|January 6, 2026
PubMed
概括

由于利潜力较低,生物制药行业对新抗生素的投资不足. 专注于致病原体一般增强剂的新战略可以解决治疗失败问题并吸引投资.

更多相关视频

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.3K
Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays
05:57

Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays

Published on: April 26, 2024

1.2K

相关实验视频

Last Updated: Jan 13, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
10:49

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

11.5K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.3K
Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays
05:57

Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays

Published on: April 26, 2024

1.2K

科学领域:

  • 微生物学 微生物学
  • 传染性疾病 传染性疾病
  • 制药科学 制药科学

背景情况:

  • 抗生素耐药性危机的特点是生物制药行业对新型抗生素投资不足.
  • 利潜力有限是开发新抗菌药物的主要障碍.

研究的目的:

  • 建议对抗生素开发的重点转变,从仅针对高度耐药的病原体转向解决经验治疗失败的问题.
  • 引入一个新的框架,以开发病原体一般增强剂为中心,以刺激行业投资.

主要方法:

  • 对抗生素发现的概念分析和框架建议.
  • 重新定义抗生素开发中的主要问题,从感染死亡率到治疗失败.

主要成果:

  • 经验性治疗失败比特定耐药病原体导致的死亡更为严重的问题.
  • 病原体一般增强剂为经验治疗失败提供了可行的解决方案.
  • 这种方法为生物制药行业提供了有吸引力的潜在利模式.

结论:

  • 重构抗生素耐药性挑战,将其转变为经验治疗失败至关重要.
  • 开发病原体一般增强剂是克服行业投资不足的一个有希望的战略.
  • 这种新的框架可以重振抗生素的发现和开发工作.